PACEVIOS Trademark

Trademark Overview


On Thursday, June 1, 2017, a trademark application was filed for PACEVIOS with the United States Patent and Trademark Office. The USPTO has given the PACEVIOS trademark a serial number of 87472239. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 30, 2019. This trademark is owned by Eli Lilly and Company. The PACEVIOS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents ...
pacevios

General Information


Serial Number87472239
Word MarkPACEVIOS
Filing DateThursday, June 1, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 30, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 3, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 8, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, December 30, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 30, 2019ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 16, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 12, 2019EXTENSION 3 GRANTED
Friday, April 12, 2019EXTENSION 3 FILED
Friday, April 12, 2019TEAS EXTENSION RECEIVED
Tuesday, October 23, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 19, 2018EXTENSION 2 GRANTED
Friday, October 19, 2018EXTENSION 2 FILED
Friday, October 19, 2018TEAS EXTENSION RECEIVED
Friday, May 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 17, 2018EXTENSION 1 GRANTED
Friday, May 4, 2018EXTENSION 1 FILED
Thursday, May 17, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 4, 2018TEAS EXTENSION RECEIVED
Tuesday, November 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 3, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 3, 2017PUBLISHED FOR OPPOSITION
Wednesday, September 13, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 15, 2017ASSIGNED TO EXAMINER
Thursday, June 8, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, June 5, 2017NEW APPLICATION ENTERED IN TRAM